Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (OPTIMUS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04901741 |
|
Recruitment Status :
Not yet recruiting
First Posted : May 25, 2021
Last Update Posted : February 1, 2024
|
Sponsor:
TME Pharma AG
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
TME Pharma AG
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2026 |
| Estimated Study Completion Date : | October 2027 |